Agenus initiates Phase 1/2 trial of zalifrelimab and balstilimab in advanced solid tumors
Agenus Inc. is conducting Phase 1/2 open-label study of zalifrelimab (AGEN1884) and balstilimab (AGEN2034) for treatment of locally advanced or metastatic solid tumors, including cervical cancer.